Advances in multiple Sclerosis and Experimental Demyelinating Diseases

Editors:

ISBN: 978-3-540-73676-9 (Print) 978-3-540-73677-6 (Online)

Table of contents (14 chapters)

  1. Front Matter

    Pages i-xiv

  2. No Access

    Book Chapter

    Pages 1-17

    Benign Multiple Sclerosis: A Distinct Clinical Entity with Therapeutic Implications

  3. No Access

    Book Chapter

    Pages 19-43

    Pathological Heterogeneity of Idiopathic Central Nervous System Inflammatory Demyelinating Disorders

  4. No Access

    Book Chapter

    Pages 45-72

    Multiple Sclerosis Genetics

  5. No Access

    Book Chapter

    Pages 73-92

    Imaging of Remyelination and Neuronal Health

  6. No Access

    Book Chapter

    Pages 93-131

    Immunological Aspects of Axon Injury in Multiple Sclerosis

  7. No Access

    Book Chapter

    Pages 133-175

    The Multiple Sclerosis Degradome: Enzymatic Cascades in Development and Progression of Central Nervous System Inflammatory Disease

  8. No Access

    Book Chapter

    Pages 177-192

    Genetic Analysis of CNS Remyelination

  9. No Access

    Book Chapter

    Pages 193-212

    Remyelination in Experimental Models of Toxin-Induced Demyelination

  10. No Access

    Book Chapter

    Pages 213-239

    Remyelination-Promoting Human IgMs: Developing a Therapeutic Reagent for Demyelinating Disease

  11. No Access

    Book Chapter

    Pages 241-266

    Neuroimaging of Demyelination and Remyelination Models

  12. No Access

    Book Chapter

    Pages 267-311

    Hormonal Influences in Multiple Sclerosis

  13. No Access

    Book Chapter

    Pages 313-324

    Statins and Demyelination

  14. No Access

    Book Chapter

    Pages 325-342

    Role of Uric Acid in Multiple Sclerosis

  15. No Access

    Book Chapter

    Pages 343-356

    Neuromyelitis Optica: Clinical Syndrome and the NMO-IgG Autoantibody Marker

  16. Back Matter

    Pages 357-362